A Phase 4 interventional study of Escitalopram and Bupropion in Major Depression and Dysthymia, sponsored by New York State Psychiatric Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-04-27.
Sponsored by New York State Psychiatric Institute · Phase 4, Interventional, and Treatment
The main purpose of this study is to correlate brain testing with treatment outcome.
40 medication-free Depressed Patients will receive a battery of neuropsychologic tests, standard dichotic listening tests, EEG, ERP and an f-MRI while performing a neuropsychologic test, the Simon. Once testing is completed, patients will be treated in an open treatment trial of SSRI. Non-responders will then receive Bupropion followed by Tricyclic Antidepressant if still depressed. While our main purpose is to correlate imaging testing with other measures of brain functioning, we also intend to see whether f-MRI findings demonstrate specific brain areas which differ between responders and non-responders. At the end of SSRI treatment, patients will have a second f-MRI scan to investigate any changes treatment and/or response may have caused.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 28 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →New York State Psychiatric Institute is the lead sponsor of 425 studies on the registry; 26 are open to participants now.
Of its 50 completed or terminated interventional studies of FDA-regulated products, 45 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
Drug: Escitalopram
bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
Drug: Bupropion
imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
Drug: Imipramine
8 weeks: up to 40 mg/day
Also known as: Lexapro
8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
Also known as: Wellbutrin
8 weeks: up to 300mg/day \*if patient does not have contraindication.
Also known as: Tofranil, Pressamine
Hamilton Depression Scale (HAM-D)
Time frame: 7 mos.
Beck Depression Inventory (BDI)
Time frame: 7 mos.
Clinical Global Impression (CGI)
Time frame: 7 mos.
Patient Global Impression (PGI)
Time frame: 7 mos.
Inventory of Depressive Symptoms (IDS)
Time frame: 7 mos.
Edinburgh Handedness Inventory
Time frame: 7 mos.
Chapman Pleasure Scale
Time frame: 7 mos.
Spielberger State/Trait Anxiety Inventory
Time frame: 7 mos.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
New York State Psychiatric Institute